

LETTER

Open Access



Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration

Gerardo Aguilar^{1,2*} , Rafael Ferriols^{2,3}, Sara Martínez-Castro^{1,2}, Carlos Ezquer^{2,3}, Ernesto Pastor^{1,2}, José A. Carbonell^{1,2}, Manuel Alós^{2,3} and David Navarro^{2,4,5}

Ceftolozane-tazobactam (C/T), the combination of a new cephalosporin with a classic β -lactamase inhibitor, is currently considered the most active betalactam antibiotic against *P. aeruginosa* [1]. Despite several case reports on C/T pharmacokinetics in critically ill patients during continuous renal replacement therapy (CRRT) [2–4], the optimal dose in this clinical scenario still remains unclear [5].

A 68-year-old patient was admitted to our ICU with septic shock (nosocomial peritonitis) and anuric acute renal failure. Broad-spectrum antimicrobial therapy, including C/T and continuous venovenous hemodiafiltration (CVVHD), was initiated, using a polysulphone hemofilter (Fresenius, Germany) with blood flow, dialysate fluid, and replacement fluid rates of 100 mL/min, 2000 mL/h, and 1000 mL/h. The patient received high C/T doses of C/T 2 g/1 g every 8 h (infused over 1 h) while receiving CVVHD, and became afebrile 7 days after C/T treatment initiation, remaining fever-free for 14 days without any adverse effects related to this drug.

Pre-filter and post-filter blood and ultrafiltrate samples were obtained during the 8-h dosing interval after the fourth dose. Drug concentrations were measured by high-performance liquid chromatography. Figure 1 and Table 1 show pre- and post-filter plasma concentrations. Pharmacokinetic parameters were calculated (Table 2). Extraction ratios were high for both ceftolozane and tazobactam ($49.3\% \pm 1.8\%$ and $40.5\% \pm 4.5\%$). Mean C/T concentrations in the ultrafiltrate were 40 mg/L and 13.5 mg/L, respectively.

We decided on a 3 g/iv dose every 8 h, taking into account two previous studies [3, 4] and a recent study which showed CRRT to be an independent predictor of clinical failure (OR 4.5, 95% CI 1.18–17.39, $p = 0.02$) when C/T is administered at 1.5 g every 8 h [5].

Ceftolozane and tazobactam are small molecules with low plasma protein binding rates, causing most to be removed during CRRT. Despite the considerable C/T clearance observed in our patients during

* Correspondence: gerardo.aguilar@uv.es

¹Critical Care Unit, Anesthesiology and Critical Care Department, Hospital Clínico Universitario de Valencia, Valencia, Spain

²INCLIVA Health Research Institute, Avenida de Menéndez y Pelayo, 4, 46010 Valencia, Spain

Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.




Fig. 1 Simulated plasma concentrations versus time curves for ceftolozane and tazobactam. Pre-filter (thick line) and post-filter (fine line) ceftolozane plasma concentrations and pre-filter (thick dotted line) and post-filter (fine dotted line) tazobactam plasma concentrations. (The figure is original for this article)

CVVHD, however, ceftolozane plasma concentrations remained above the MIC, for MICs of up to 8 µg/mL, throughout the dosing interval, assuming 20% protein binding. Given that C/T exhibits linear, dose-proportional pharmacokinetics, a standard C/T dose of 1 g/0.5 g would be expected to maintain ceftolozane levels above the MIC during the entire dosing interval, although tazobactam concentrations

could be insufficient, even taking higher pre-filter rather than lower post-filter levels as representative of therapeutic serum levels.

In conclusion, our data underscore that a dosage of 3 g every 8 h can be used safely to prevent the potential harm of underdosing ceftolozane/tazobactam during CRRT; larger studies are however needed to confirm our findings.

Table 1 Concentrations of ceftolozane and tazobactam in pre-filter and post-filter plasma samples obtained after the fourth dose of 2 g/1 g ceftolozane-tazobactam administered as intravenous 1-h infusion

Sampling time	Ceftolozane (mg/L)		Tazobactam (mg/L)	
	Pre-filter	Post-filter	Pre-filter	Post-filter
0 h (pre dose)	41.9	20.7	10.6	5.8
1.5 h post dose	89.1	45.2	28.3	12.2
2 h post dose	80.3	38.4	21.6	10.3
2.5 h post dose	77.1	36.1	19.0	9.0
3 h post dose	73.8	34.7	16.3	8.2
5 h post dose	66.6	30.6	14.2	7.4
7 h post dose	60.2	28.7	12.7	6.0
8 h post dose	55.8	25.8	11.4	5.1

Table 2 Pharmacokinetic parameters of ceftolozane and tazobactam

Parameter	Ceftolozane		Tazobactam	
	Pre-filter	Post-filter	Pre-filter	Post-filter
Clearance (L/h)	2.1	5.4	6.4	17.4
Volume of distribution (L)	53.9	97.5	108.9	194.2
Half-life (h)	17.9	12.6	11.9	7.8
AUC (h mg/L)	960	373	157	57.6
Maximum concentration (mg/L)	99	53	37	14.5
Minimum concentration (mg/L)	55.9	25.8	11.4	5.1

AUC area under the concentration-time curve

Abbreviations

AUC: Area under the concentration-time curve; C/T: Ceftolozane-tazobactam; CRRT: Continuous renal replacement therapy; CWHD: Continuous venovenous hemodiafiltration; HPLC: High-performance liquid chromatography

Acknowledgements

Not applicable.

Funding

Not applicable.

Availability of data and materials

All relevant data are within the paper and its supporting information files. All data are fully available without restriction.

Authors' contributions

GA conceived the study, participated in its design, and drafted the manuscript. RF participated in the study design and coordination and helped draft the manuscript. CE performed pharmacokinetics analysis and helped revise the manuscript. SMC, EP, JC, and participated in data analysis and interpretation and helped revise the manuscript. DN and MA participated in the study design and coordination and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study protocol (TC-TCRR-2018) was approved by the local ethics committee (INCLIVA Health Research Institute) and written informed consent obtained from the patients or their relatives prior to study inclusion.

Consent for publication

Written informed consent was obtained from the patient or their relatives for publication of their individual details. The consent form is held by the authors' institution and is available for review by the Editor-in-Chief.

Competing interests

GA received financial support for speaking at meetings organized on behalf of Astellas, Gilead, Merck Sharp and Dohme (MSD), and Pfizer, as well as unrestricted research grants from Astellas, MSD, and Pfizer. DN received financial support for speaking at meetings organized on behalf of Astellas, MSD, and Pfizer and received unrestricted research grants from Astellas and Pfizer. All other authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Critical Care Unit, Anesthesiology and Critical Care Department, Hospital Clínico Universitario de Valencia, Valencia, Spain. ²INCLIVA Health Research Institute, Avenida de Menéndez y Pelayo, 4, 46010 Valencia, Spain. ³Department of Pharmacy, Hospital Clínico Universitario de Valencia, Avenida Blasco Ibáñez, 17, 46010 Valencia, Spain. ⁴Department of Microbiology, Hospital Clínico Universitario de Valencia, Avenida Blasco Ibáñez, 17, 46010 Valencia, Spain. ⁵School of Medicine, University of Valencia, Avenida Blasco Ibáñez, 15, 46010 Valencia, Spain.

Received: 14 February 2019 Accepted: 10 April 2019

Published online: 26 April 2019

References

- Montravers P, Bassetti M. The ideal patient profile for new beta-lactam/beta-lactamase inhibitors. *Curr Opin Infect Dis*. 2018;31(6):587–e93.
- Oliver WD, Heil EL, Gonzales JP, Mehrotra S, Robinett K, Saleeb P, Nicolau DP. Ceftolozane-tazobactam pharmacokinetics in a critically ill patient on continuous venovenous hemofiltration. *Antimicrob Agents Chemother*. 2015;60(3):1899–901.
- Kuti JL, Ghazi IM, Quintiliani R Jr, Shore E, Nicolau DP. Treatment of multidrug-resistant *Pseudomonas aeruginosa* with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. *Int J Antimicrob Agents*. 2016;48:342–3.

- Bremmer DN, Nicolau DP, Burcham P, Chunduri A, Shidham G, Bauer KA. Ceftolozane/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy. *Pharmacotherapy*. 2016;36:e30–e3.
- Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, et al. Ceftolozane/tazobactam for the treatment of serious *P. aeruginosa* infections: a multicenter nationwide clinical experience. *Int J Antimicrob Agents*. 2018; [Epub ahead of print].

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

